Takeda Pharmaceutical Company Limited based in Tokyo and Cour Pharmaceutical Development Company, Inc. announces partnership to research and develop immune modulating therapies for the potential treatment of celiac disease, according to a 7 December Press Release.
“Cour is very pleased to be partnering with Takeda, and our collaboration marks an important breakthrough in the development of therapies for patients suffering from celiac disease,” said John J. Puisis, CEO and co-founder of Cour. “Takeda is the ideal partner based on the company’s strong foundation in gastroenterology and expertise in the discovery and development of therapies meeting unmet needs in patients suffering from gastrointestinal diseases.”
Full Press Release here.
